Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821155 | 0.89 | — | — | |
| Acetic Acid SCHEMBL28649864 | 0.85 | LMNA (0.45) | TDP1LMNASLC15A2CYP3A4MAPT | |
| SCHEMBL5943258 | 0.84 | LMNA (0.47) | TDP1LMNACYP3A4MAPTMEN1 | |
| Succinic Acid SCHEMBL27929020 | 0.84 | LMNA (0.47) | TDP1LMNAALDH1A1SLC15A2HSD17B10 | |
| Fumaric Acid SCHEMBL4881929 | 0.82 | USP2 (0.44) | TDP1LMNAALDH1A1HSD17B10USP2 | |
| SCHEMBL3503355 | 0.82 | USP2 (0.42) | TDP1LMNAALDH1A1SLC15A2HSD17B10 | |
| SCHEMBL12863645 | 0.79 | ALDH1A1 (0.51) | TDP1LMNAALDH1A1HSD17B10USP2 | |
| Methoxymethane SCHEMBL2178813 | 0.78 | USP2 (0.41) | TDP1LMNAALDH1A1SLC15A2HSD17B10 | |
| SCHEMBL304203 | 0.78 | TDP1 (0.54) | TDP1LMNAALDH1A1HSD17B10USP2 | |
| SCHEMBL1456240 | 0.77 | LMNA (0.57) | TDP1LMNAALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358748-A1 | AMORPHOUS DISPERSION OF FERRIC MALTOL AND THE PREPARATION PROCESS THEREOF | INDENA S.P.A. (IT) | 2024-10-31 | — | — | US | claimed |
| EP-4370100-A1 | AMORPHOUS DISPERSION OF FERRIC MALTOL AND THE PREPARATION PROCESS THEREOF | Indena S.p.A. (IT) | 2024-05-22 | — | — | EP | claimed |
| US-20240148660-A1 | PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORES | AbbVie Pharmaceuticals GmbH (DE) | 2024-05-09 | — | — | US | claimed |
| WO-2023285979-A1 | AMORPHOUS DISPERSION OF FERRIC MALTOL AND THE PREPARATION PROCESS THEREOF | INDENA S.P.A. (IT) | 2023-01-19 | — | — | WO | claimed |
| CN-114945357-A | Solid dosage form comprising bacteria and microbial extracellular vesicles | 伊夫罗生物科学公司 | 2022-08-26 | — | — | CN | claimed |
| US-20220183988-A1 | PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORES | ABBOTT PRODUCTS GMBH (DE) | 2022-06-16 | — | — | US | claimed |
| US-11266607-B2 | Process for the manufacture and use of pancreatin micropellet cores | AbbVie Pharmaceuticals GmbH (DE) | 2022-03-08 | — | — | US | claimed |
| US-20210353722-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS | AbbVie Pharmaceuticals GmbH (DE) | 2021-11-18 | — | — | US | claimed |
| US-20210060142-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS | ABBOTT PRODUCTS GMBH (DE) | 2021-03-04 | — | — | US | claimed |
| CN-111419813-A | Metoprolol succinate sustained-release tablet and preparation method thereof | 深圳市道科思医药有限公司 | 2020-07-17 | — | — | CN | claimed |
| EP-1931316-B1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS | SOLVAY PHARM GMBH (DE) | 2010-02-17 | — | — | EP | claimed |
| WO-2009118756-A2 | DELAYED RELEASE COMPOSITIONS OF DULOXETINE | LUPIN LIMITED (IN) | 2009-10-01 | — | — | WO | claimed |
| US-20090117180-A1 | STABLE DIGESTIVE ENZYME COMPOSITIONS | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2009-05-07 | — | — | US | claimed |
| EP-1931317-B1 | PANCREATIN MICROPELLETS SUITABLE FOR ENTERIC COATING | SOLVAY PHARM GMBH (DE) | 2008-12-24 | — | — | EP | claimed |
| EP-1931317-A2 | PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING | Solvay Pharmaceuticals GmbH (DE) | 2008-06-18 | — | — | EP | claimed |
| EP-1931316-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS | Solvay Pharmaceuticals GmbH (DE) | 2008-06-18 | — | — | EP | claimed |
| US-20070148153-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS | ABBOTT PRODUCTS GMBH (DE) | 2007-06-28 | — | — | US | claimed |
| US-20070148152-A1 | PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORES | AbbVie Pharmaceuticals GmbH (DE) | 2007-06-28 | — | — | US | claimed |
| WO-2007020260-A2 | PANCREATIN MICROPELLET CORES SUITABLE FOR ENTERIC COATING | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-02-22 | — | — | WO | claimed |
| WO-2007020259-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID LABILE DRUGS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-02-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358748-A1 | AMORPHOUS DISPERSION OF FERRIC MALTOL AND THE PREPARATION PROCESS THEREOF | MGAM, SORD, SLC40A1 | TDP1 3738/4885LMNA 3327/4885ALDH1A1 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.